Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Vaccination | Research

The resurgence of yellow fever outbreaks in Nigeria: a 2-year review 2017–2019

Authors: Terna Nomhwange, Anne Eudes Jean Baptiste, Obi Ezebilo, Joseph Oteri, Lois Olajide, Kizito Emelife, Shehu Hassan, Erdoo R. Nomhwange, Kennedy Adejoh, Faith Ireye, Eyo E. Nora, Adamu Ningi, Blaise Bathondeli, Oyewale Tomori

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Yellow fever outbreaks are documented to have a considerable impact not only on the individuals but on the health system with significant economic implications. Efforts to eliminate yellow fever outbreaks globally through the EYE strategy remains important following outbreaks in Africa, Nigeria included. The outbreaks reported in Nigeria, since 2017 and the response efforts provide an opportunity to document and guide interventions for improving future outbreaks in Nigeria and other countries in Africa.

Methods

We reviewed the available yellow fever surveillance and vaccination response data between September 2017 and September 2019 across the 36 states across Nigeria. We described the epidemiology of the difference outbreaks and the periods for all interventions. We also documented the emergency vaccination responses as well as preventive mass vaccinations implemented towards improving population immunity and limiting epidemic potentials in Nigeria.

Results

A total of 7894 suspected cases with 287 laboratory-confirmed cases were reported in Nigeria between September 2017 and September 2019 with a mean age of 19 years and a case fatality of 2.7% amongst all reported cases. Outbreaks were confirmed in 55 LGAs with most of the outbreaks across four major epicentres in Kwara/Kogi, Edo, Ebonyi and Bauchi states. In response to these outbreaks, eight reactive vaccination campaigns, supported through ICG applications, were implemented. The duration for responding to the outbreaks ranged from 15 to 132 days (average 68 days) and a total of 45,648,243 persons aged < 45 years vaccinated through reactive and preventive mass campaigns between September 2017 and September 2019.

Conclusions

Nigeria experienced intermediate outbreaks of yellow fever between September 2017 and 2019 with vaccination responses conducted to control these outbreaks. However, there are delays in the timeliness of responses and more efforts required in improving reporting, response times and preparedness to further prevent morbidity and mortality from the yellow fever disease outbreaks. These efforts, including improving routine yellow fever coverage, contribute towards improving population immunity and other activities related to achieving the goals of the EYE strategy.
Literature
7.
go back to reference Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination strategies. Trop Dis Travel Med Vaccines. 2020;6:1.CrossRef Chen LH, Wilson ME. Yellow fever control: current epidemiology and vaccination strategies. Trop Dis Travel Med Vaccines. 2020;6:1.CrossRef
8.
go back to reference Souza NCSE, et al. Evaluation of serological cross-reactivity between yellow fever and other flaviviruses. Int J Infect Dis. 2019;81:4–5.CrossRef Souza NCSE, et al. Evaluation of serological cross-reactivity between yellow fever and other flaviviruses. Int J Infect Dis. 2019;81:4–5.CrossRef
12.
go back to reference Adrien N, et al. Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: a desk review of global data sources. Vaccine. 2019;37:4511–7.CrossRef Adrien N, et al. Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: a desk review of global data sources. Vaccine. 2019;37:4511–7.CrossRef
14.
go back to reference Shearer FM, et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017;17:1209–17.CrossRef Shearer FM, et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017;17:1209–17.CrossRef
15.
go back to reference Chippaux JP, Chippaux A. Yellow fever in Africa and the Americas: a historical and epidemiological perspective. J Venom Anim Toxins Incl Trop Dis. 2018;24:20.CrossRef Chippaux JP, Chippaux A. Yellow fever in Africa and the Americas: a historical and epidemiological perspective. J Venom Anim Toxins Incl Trop Dis. 2018;24:20.CrossRef
20.
21.
go back to reference Gubler DJ. Potential yellow fever epidemics in unexposed populations. Bull World Health Organ. 2018;96:299.CrossRef Gubler DJ. Potential yellow fever epidemics in unexposed populations. Bull World Health Organ. 2018;96:299.CrossRef
22.
go back to reference Nicholson A, Snair MR, Hermann J. Global health risk framework. Global health risk framework. Washington: National Academies Press; 2016.CrossRef Nicholson A, Snair MR, Hermann J. Global health risk framework. Global health risk framework. Washington: National Academies Press; 2016.CrossRef
23.
go back to reference Chan EH, et al. Global capacity for emerging infectious disease detection. Proc Natl Acad Sci U S A. 2010;107:21701–6.CrossRef Chan EH, et al. Global capacity for emerging infectious disease detection. Proc Natl Acad Sci U S A. 2010;107:21701–6.CrossRef
24.
go back to reference Possas C, et al. Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation. Mem Inst Oswaldo Cruz. 2018;113: e180278.CrossRef Possas C, et al. Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation. Mem Inst Oswaldo Cruz. 2018;113: e180278.CrossRef
Metadata
Title
The resurgence of yellow fever outbreaks in Nigeria: a 2-year review 2017–2019
Authors
Terna Nomhwange
Anne Eudes Jean Baptiste
Obi Ezebilo
Joseph Oteri
Lois Olajide
Kizito Emelife
Shehu Hassan
Erdoo R. Nomhwange
Kennedy Adejoh
Faith Ireye
Eyo E. Nora
Adamu Ningi
Blaise Bathondeli
Oyewale Tomori
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Vaccination
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06727-y

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.